Redwood Investments LLC Sells 16,641 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Redwood Investments LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,189 shares of the biopharmaceutical company's stock after selling 16,641 shares during the period. Redwood Investments LLC's holdings in Halozyme Therapeutics were worth $1,539,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in HALO. Fiduciary Alliance LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at about $398,000. Park Avenue Securities LLC lifted its stake in Halozyme Therapeutics by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company's stock valued at $595,000 after buying an additional 801 shares in the last quarter. Redhawk Wealth Advisors Inc. grew its position in Halozyme Therapeutics by 3.4% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 38,035 shares of the biopharmaceutical company's stock worth $1,818,000 after purchasing an additional 1,267 shares in the last quarter. Outlook Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth about $355,000. Finally, Argent Capital Management LLC boosted its holdings in shares of Halozyme Therapeutics by 35.1% during the fourth quarter. Argent Capital Management LLC now owns 12,841 shares of the biopharmaceutical company's stock worth $614,000 after purchasing an additional 3,339 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,697 shares of company stock valued at $1,276,552. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Up 0.2%

Shares of HALO traded up $0.11 on Tuesday, hitting $53.41. The company's stock had a trading volume of 792,217 shares, compared to its average volume of 1,833,077. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.50. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm's fifty day moving average price is $60.54 and its 200-day moving average price is $55.95. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 15.57, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on HALO. HC Wainwright reiterated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Finally, Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.